Abstract:Background : The measurement of neurofilament light (NFL) in blood samples has been established as a sensitive measure of neuroaxonal damage in a wide range of diseases in the peripheral and central nervous system, including multiple sclerosis (MS). Previous studies have identified confounding factors that may influence the serum concentration of NFL. Aim : We aimed at investigating the relationship between known confounders (age, body mass index, blood volume) and risk factors for MS (smoking and human leukocyte antigen (HLA)) on serum concentrations of NFL in control subjects. In addition, we compared different methods for correction for confounders when applied to newly diagnosed patients with MS. Methods : We measured serum concentrations of NFL by single molecule array analysis in 1.101 control subjects without neurological disease from 4 different cohorts (including 906 healthy blood donors) and 72 patients with newly diagnosed relapsing-remitting MS. A questionnaire on smoking habits was distributed to the 906 healthy blood donors, and the HLA risk alleles DRB1*15:01 and HLA-A*02:01 were genotyped by TaqMan allelic-discrimination PCR analysis in these subjects. Results : We confirmed that serum concentrations of NFL increase with age, but we also found that sample storage conditions for the different cohorts of control subjects had a substantial effect. Prolonged storage time and storage at -20° were independently associated with lower serum concentrations of NFL than shorter storage time and storage at -80°. In samples from the large cohort of blood donors, we confirmed an association between high BMI and high blood volume with lower serum concentrations of NFL and found that this association was marginally stronger for BMI than for blood volume. We found no association between smoking and HLA risk factors for MS with serum concentrations of NFL in the blood donor cohort. Finally, we found that a simple method for correcting for the effect of age on NFL performed as well as Z-scores, which consider the effect of both age and BMI. This was shown when discriminating between patients with MS and control subjects and between MS patients with and without Gd-enhancing MRI lesions. Conclusions : We confirm an association between serum concentrations of NFL, age, and BMI, but we also find that it may often be sufficient to correct for the effect of age alone. The effect of BMI should, however, be considered along with the effect of other confounding factors, including various comorbidities.

Enhancing the clinical value of serum neurofilament light chain measurement

In multiple sclerosis patients a single serum neurofilament light chain (sNFL) dosage is strongly associated with 12 months outcome: data from a real-life clinical setting

Cerebrospinal Fluid Neurofilament Light Chain (NfL) Predicts Disease Aggressiveness in Amyotrophic Lateral Sclerosis: An Application of the D50 Disease Progression Model

CSF neurofilament light chain profiling and quantitation in neurological diseases

Serum GFAP and NfL Levels Differentiate Subsequent Progression and Disease Activity in Patients With Progressive Multiple Sclerosis

Predictive value of individual serum neurofilament light chain levels in short-term disease activity in relapsing multiple sclerosis

The potential of serum neurofilament as biomarker for multiple sclerosis

CSF Neurofilament Light Chain Elevation Predicts ALS Severity and Progression

Increased Neurofilament Light Chain Blood Levels in Neurodegenerative Neurological Diseases

Neurofilament light chain in serum for the diagnosis of amyotrophic lateral sclerosis

High serum neurofilament light chain levels correlate with brain atrophy and physical disability in multiple sclerosis

Serum neurofilament light chain concentration predicts disease worsening in multiple sclerosis

Impact of serum neurofilament light on clinical decisions in a tertiary multiple sclerosis clinic

Guidance for use of neurofilament light chain as a cerebrospinal fluid and blood biomarker in multiple sclerosis management

Evaluation of cerebrospinal fluid neurofilament light chain levels in multiple sclerosis and non-demyelinating diseases of the central nervous system: clinical and biochemical perspective

Serum NFL levels predict progression of motor impairment and reduction in putamen dopamine transporter binding ratios in de novo Parkinson's disease: An 8-year longitudinal study.

Neurofilament light in serum: reference values and effect of risk factors for multiple sclerosis

Accuracy of serum neurofilament light to identify contrast-enhancing lesions in multiple sclerosis

Evaluating the utility of serum NfL, GFAP, UCHL1 and tTAU as estimates of CSF levels and diagnostic instrument in neuroinflammation and multiple sclerosis

Patients with Amyotrophic Lateral Sclerosis and Other Neurodegenerative Diseases Have Increased Levels of Neurofilament Protein in CSF

Neurofilament light chain as a biomarker in neurological disorders